Amarin Corp Plc (AMRN) is a publicly traded Healthcare sector company. As of May 21, 2026, AMRN trades at $14.16 with a market cap of $294.83M and a P/E ratio of -177.50. AMRN moved +0.00% today. Year to date, AMRN is +5.70%; over the trailing twelve months it is +28.44%. Its 52-week range spans $7.08 to $20.90. Analyst consensus is sell with an average price target of $12.00. Rallies surfaces AMRN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
REDUCE-IT Post-Hoc Analysis: Icosapent Ethyl Lowers Events in 8,179 Extreme Risk Patients: At ACC Scientific Sessions 2026, Amarin-supported analysis of 8,179 REDUCE-IT trial participants at extreme cardiovascular risk showed icosapent ethyl reduced events vs placebo; poster data indicated EPA inhibits lipoprotein(a) oxidation. Updated 2026 ACC/AHA dyslipidemia guidelines now highlight elevated triglycerides as a residual risk factor and endorse complementary therapies beyond statins.
| Metric | Value |
|---|---|
| Price | $14.16 |
| Market Cap | $294.83M |
| P/E Ratio | -177.50 |
| EPS | $-0.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.90 |
| 52-Week Low | $7.08 |
| Volume | 209 |
| Avg Volume | 0 |
| Revenue (TTM) | $216.76M |
| Net Income | $-33.61M |
| Gross Margin | 52.37% |
1 analysts cover AMRN: 0 strong buy, 0 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is sell. Average price target: $12.00.